Come and join us on 6 July and hear 4 AIM CEO’s speak. Brad George, Orosur CEO updates us on Colombia’s Tier-1 gold mine potential, Cliff Gross, CEO at Tekcapital explains how investors benefit from a special dividend. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAmryt Pharma Share News (AMYT)

Share Price Information for Amryt Pharma (AMYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 166.00
Bid: 165.00
Ask: 170.00
Change: -1.50 (-0.90%)
Spread: 5.00 (3.03%)
Open: 167.50
High: 166.00
Low: 166.00
Yest. Close: 167.50
AMYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Director dealings: Amryt Pharma chairman makes share purchase

Mon, 15th Mar 2021 16:38

(Sharecast News) - Amryt Pharma revealed on Monday that chairman Ram Stafford had acquired 300,100 ordinary shares in the AIM-listed commercial-stage biopharmaceutical company.
Stafford, who previously headed up Sudocrem owner Tosara Group, purchased the shares on Friday at an average price of 200.0p per share, for a total value of £600,200.

Last week, Amryt announced the signing of a distribution agreement with Medison Pharma to distribute its Myalepta product in Canada.

Amryt said the agreement completed its multi-regional distribution deals with Medison, first announced in February, to distribute Myalepta and Lojuxta in Israel and Juxtapid in Canada.

As of 1645 GMT, Amryt shares were up 3.54% at 205.0p.

Top Director Buys

Amryt Pharma (AMYT)
Director name: Stafford,Ray
Amount purchased: 300,100 @ 200.00p
Value: £600,200.00

Newriver Reit (NRR)
Director name: Lockhart,Allan
Amount purchased: 224,489 @ 97.58p
Value: £219,056.36

Newriver Reit (NRR)
Director name: Davies,Mark
Amount purchased: 185,000 @ 96.20p
Value: £177,970.00

Photo-me International (PHTM)
Director name: Crasnianski,Serge
Amount purchased: 282,029 @ 51.11p
Value: £144,145.02

Photo-me International (PHTM)
Director name: Crasnianski,Serge
Amount purchased: 250,000 @ 51.35p
Value: £128,374.99

Edinburgh Worldwide Inv Trust (EWI)
Director name: Wilson,Mungo
Amount purchased: 35,613 @ 350.50p
Value: £124,823.57

W Resources (WRES)
Director name: Masterman,Michael
Amount purchased: 95,000,000 @ 0.09p
Value: £86,402.50

Serco Group (SRP)
Director name: Lodge,Tim
Amount purchased: 40,000 @ 127.20p
Value: £50,880.00

Frenkel Topping Group (FEN)
Director name: Mills,Christopher
Amount purchased: 100,000 @ 45.00p
Value: £45,000.00

W Resources (WRES)
Director name: Masterman,Michael
Amount purchased: 37,000,000 @ 0.09p
Value: £31,524.00

F&c Investment Trust (FCIT)
Director name: Joy,Tom
Amount purchased: 3,500 @ 788.86p
Value: £27,610.10

W Resources (WRES)
Director name: Masterman,Michael
Amount purchased: 18,000,000 @ 0.09p
Value: £16,830.00

Lxi Reit (LXI)
Director name: Dimond,Patricia
Amount purchased: 8,005 @ 124.92p
Value: £9,999.53

Rockfire Resources (ROCK)
Director name: Walley,Nicholas
Amount purchased: 536,000 @ 0.95p
Value: £5,092.00

F&c Investment Trust (FCIT)
Director name: Ecsery,Francesca
Amount purchased: 380 @ 783.48p
Value: £2,977.24



Top Director Sells

Pagegroup (PAGE)
Director name: Ingham,Stephen
Amount sold: 41,638 @ 480.10p
Value: £199,904.04

Newriver Reit (NRR)
Director name: Davies,Mark
Amount sold: 185,000 @ 96.20p
Value: £177,970.00

Dukemount Capital (DKE)
Director name: Dart,Geoffrey
Amount sold: 27,000,000 @ 0.60p
Value: £162,000.00

Newriver Reit (NRR)
Director name: Lockhart,Allan
Amount sold: 133,745 @ 97.20p
Value: £130,000.14

Pagegroup (PAGE)
Director name: Stagg ,Kelvin
Amount sold: 20,774 @ 480.10p
Value: £99,735.98

Cropper (james) (CRPR)
Director name: Maddock,Isabelle
Amount sold: 500 @ 1,100.00p
Value: £5,500.00

More News

Cathal Friel-led Poolbeg Pharma set to float on AIM

(Sharecast News) - Infectious disease specialist Poolbeg Pharma is to list on the London Stock Exchange's junior market, AIM, with a view to raising the funds needed to develop its product pipeline.

17 Jun 21 14:34

BUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall

BUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall

3 Jun 21 19:20

FDA grants Amryt's Oleogel-S10 priority review status

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced on Thursday that the United States Food and Drug Administration (FDA) has granted priority review status for the new drug application for 'Oleogel-S10', for the treatment of epidermolysis bullosa (EB).

3 Jun 21 11:26

TRADING UPDATES: Block Energy 2020 revenue jumps; Kanabo loss narrows

TRADING UPDATES: Block Energy 2020 revenue jumps; Kanabo loss narrows

2 Jun 21 19:10

TRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million

TRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million

5 May 21 19:20

EXECUTIVE CHANGES: Rosslyn promotes new CEO; Celtic CEO ready to start

EXECUTIVE CHANGES: Rosslyn promotes new CEO; Celtic CEO ready to start

6 Apr 21 14:54

Amryt completes rolling FDA submission for Oleogel-S10

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma has completed the rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for 'Oleogel-S10', it announced on Wednesday, for the potential treatment of cutaneous manifestations of junctional and dystrophic epidermolysis bullosa (EB).

31 Mar 21 11:50

Amryt releases data from Italy lomitapide study

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma released efficacy and safety data from the 'Lochnes' investigator-sponsored study of lomitapide in familial chylomicronemia syndrome (FCS) on Tuesday, which was conducted by expert lipidologists in Italy.

30 Mar 21 12:11

European approval for Amryt's Oleogel-S10 moves closer

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced the validation of its marketing authorisation application for 'Oleogel-S10' by the European Medicines Agency on Monday, for the potential treatment of cutaneous manifestations of junctional and dystrophic epidermolysis bullosa.

29 Mar 21 09:15

IN BRIEF: Amryt gets positive feedback on Myalept from US regulator

IN BRIEF: Amryt gets positive feedback on Myalept from US regulator

23 Mar 21 19:03

Amryt upbeat on positive FDA feedback

(Sharecast News) - Commercial-stage biopharmaceuticals company Amryt Pharma has received further feedback from the United States Food and Drug Administration (FDA) on Myalept, it said on Tuesday, and its proposed development plan and study design to support an indication for patients with partial lipodystrophy (PL).

23 Mar 21 09:34

IN BRIEF: Amryt's Myalepta secures reimbursement approval in France

IN BRIEF: Amryt's Myalepta secures reimbursement approval in France

22 Mar 21 19:07

Amryt's Myalepta gets reimbursement approval in France

(Sharecast News) - Commercial-stage biopharmaceuticals company Amryt Pharma announced on Monday that the French Ministry of Social Affairs and Health has approved 'Myalepta', or metreleptin, for reimbursement in the country as an adjunct to diet as replacement therapy.

22 Mar 21 09:04

Director dealings: Amryt Pharma chairman makes share purchase

(Sharecast News) - Amryt Pharma revealed on Monday that chairman Ram Stafford had acquired 300,100 ordinary shares in the AIM-listed commercial-stage biopharmaceutical company.

15 Mar 21 16:38

IN BRIEF: Amryt, Medison sign distribution deal for Myalepta in Canada

IN BRIEF: Amryt, Medison sign distribution deal for Myalepta in Canada

9 Mar 21 06:55

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.